That investors are disappointed is no surprise, according to Per Hansen.
There is no one who can measure up to Novo Nordisk in Denmark. It is where most investors have invested their money and many have put in extra money.
Hansen points out that the stock market downturn, after a study on the weight loss drug Cagrisema that did not meet expectations, is so extensive that it can have consequences for the Danish economy as a whole.
For the Danish economy, Novo Nordisk has been a locomotive. When the Danish economy, excluding Novo Nordisk, has had a growth rate of zero, Novo Nordisk has had the ability to lift the economy by a few percent.
Weakened Danish krone
The Danish krone has weakened after the stock market collapse, writes the Danish newspaper Berlingske.
According to Søren Kristensen, chief economist at Sydbank, it is due to the company's "swollen" surplus on Denmark's balance of payments.
"The large surplus is largely exchanged for Danish kronor, and therefore creates a high demand for Danish kronor in the first place," writes Kristensen in a comment to Ritzau.
Buying shares on sale
At Nordnet, 30 percent of customers own shares in the company and in recent years it has become a popular share.
Danish entrepreneur Martin Buch Thorborg writes on X that it is "a sale on Novo shares" and that he has just bought with a 22 percent discount.
On Friday afternoon, there is an exceptionally high activity in the share, says Frida Bratt, savings economist at Swedish Nordnet.
And almost all transactions in the share are purchases, so people are taking advantage of the dip, she says.
"Really sad"
Other Danish investors choose to hold on to their current shares.
The new study does not change my opinion that Novo Nordisk is a fantastic company, even though this is clearly a step in the wrong direction. It is really sad, says Lars Hytting at the asset management company Artha Scope to Berlingske.
